
Opinion|Videos|September 30, 2024
Early Diagnosis and Management, Unmet Needs and Treatment Challenges in Pediatric Plaque Psoriasis
Author(s)Karan Lal, DO, MS, FAAD, Helen T Shin, MD
Karan Lal, DO, and Helen T Shin, MD, discuss how early diagnosis of pediatric plaque psoriasis significantly improves management strategies and enhances long-term outcomes by allowing for timely intervention and personalized treatment plans.
Advertisement
Video content above is prompted by the following:
- How does early diagnosis impact the management and long-term outcomes of pediatric plaque psoriasis? (
Herbert, 2023 )
Advertisement
Related to this article

Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.

LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Revises TB Evaluation Guidance for SKYRIZI
2
Biologics, JAK Inhibitors, and Atopic March Data in Pediatric Atopic Dermatitis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5



